Search hospitals > Iowa > Clive

Iowa Digestive disease center

Claim this profile
Clive, Iowa 50325
Global Leader in Crohn's Disease
Conducts research for Ulcerative Colitis
Conducts research for Colitis
Conducts research for Gastrointestinal Diseases
Conducts research for Nonalcoholic Steatohepatitis
34 reported clinical trials
1 medical researcher
Photo of Iowa Digestive disease center in ClivePhoto of Iowa Digestive disease center in Clive

Summary

Iowa Digestive disease center is a medical facility located in Clive, Iowa. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Colitis, Gastrointestinal Diseases, Nonalcoholic Steatohepatitis and other specialties. Iowa Digestive disease center is involved with conducting 34 clinical trials across 39 conditions. There are 1 research doctors associated with this hospital, such as Bernard Leman, MD.

Top PIs

Bernard Leman, MDIowa Digestive Disease Center4 years of reported clinical research
Studies Ulcerative Colitis
Studies Psychogenic Colitis
3 reported clinical trials
2 drugs studied

Clinical Trials running at Iowa Digestive disease center

Crohn's Disease
Image of trial facility.

Tulisokibart

for Crohn's Disease

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Recruiting1 award Phase 31 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at Iowa Digestive disease center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security